127 related articles for article (PubMed ID: 37960866)
1. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
[TBL] [Abstract][Full Text] [Related]
2. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
3. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
4. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
[TBL] [Abstract][Full Text] [Related]
5. Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke.
Salam T; Desai U; Lefebvre P; Jian-Yu E; Greatsinger A; Zacharia N; Laliberté F; Bookhart B; Kharat A
Adv Ther; 2023 Oct; 40(10):4523-4544. PubMed ID: 37568060
[TBL] [Abstract][Full Text] [Related]
6. A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia.
Lin D; Pilon D; Morrison L; Shah A; Lafeuille MH; Lefebvre P; Benson C
Drugs Real World Outcomes; 2023 Sep; 10(3):471-480. PubMed ID: 37289413
[TBL] [Abstract][Full Text] [Related]
7. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
8. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
10. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
12. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
13. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
14. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
15. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States.
Li P; Benson C; Geng Z; Seo S; Patel C; Doshi JA
J Med Econ; 2023; 26(1):525-536. PubMed ID: 36961119
[TBL] [Abstract][Full Text] [Related]
17. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
[TBL] [Abstract][Full Text] [Related]
18. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
19. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
20. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
